This inventor holds 2 USPTO granted patents and 10 published patent applications. Top assignees: Ares Capital Corporation, as Agent, Modernatx, Inc.. Active years: 2024-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024-2026
Title: Innovations of Nicholas Valiante in mRNA Technology
Introduction
Nicholas Valiante is an accomplished inventor based in Cambridge, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of mRNA vaccines. His innovative work has the potential to impact cancer treatment and other medical applications.
Latest Patents
Valiante holds a patent for "Concatemeric peptide epitope RNAs." This invention relates to concatemeric peptide epitope RNAs, as well as methods and compositions thereof. The patent also includes mRNA vaccines, which are crucial for advancing cancer therapies.
Career Highlights
Nicholas Valiante is currently associated with ModernaTX, Inc., a leading biotechnology company known for its groundbreaking work in mRNA technology. His role at the company allows him to collaborate with other experts in the field and contribute to innovative solutions in healthcare.
Collaborations
Valiante has worked alongside notable colleagues such as Giuseppe Ciaramella and Eric Yi-Chun Huang. Their combined expertise enhances the research and development efforts at ModernaTX, Inc.
Conclusion
Nicholas Valiante's contributions to mRNA technology and his patent on concatemeric peptide epitope RNAs highlight his role as a key innovator in the biotechnology sector. His work continues to pave the way for advancements in medical treatments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile